KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma.

doi:10.1001/jamanetworkopen.2024.53588

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma.

JAMA network open - 2 Jan 2025

Norton Carter, Shaw Matthew Steven, Rubnitz Zachary, Smith Jarrod, Soares Heloisa P, Nevala-Plagemann Christopher D, Garrido-Laguna Ignacio, Florou Vaia

Abstract excerpt

Importance: Despite the high prevalence of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC), the clinical impact of common KRAS mutations with different cytotoxic regimens is unknown. This evidence is important to inform current treatment and provide a benchmark for emergent targeted KRAS therapies in metastatic PDAC. Objective: To assess the clinical implications of common KRAS G12 mutations in PDAC...

Read the complete abstract on PubMed

Topics

Humans
Male
Pancreatic Neoplasms
Female
Proto-Oncogene Proteins p21(ras)
Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Retrospective Studies

Mutation

Middle Aged

Antineoplastic Combined Chemotherapy Protocols

Carcinoma, Pancreatic Ductal

Treatment Outcome

Adenocarcinoma

Fluorouracil

Leucovorin

Oxaliplatin

Irinotecan

Aged, 80 and over

Source

Open in PubMed Open full text

Identifiers

PMID: 39777438
DOI: 10.1001/jamanetworkopen.2024.53588
PMCID: PMC11707629

Genes

KRAS

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 18 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma.PMID 39777438Read ↗

Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Prognostic value of KRAS gene mutations in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.Semantic proximity Read ↗

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.Semantic proximity Read ↗

Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.Semantic proximity Read ↗

MEK inhibitor-based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations.Semantic proximity Read ↗

Distinct Molecular and Clinical Features of Specific Variants of KRAS Codon 12 in Pancreatic Adenocarcinoma.Semantic proximity Read ↗

The KRAS targeting revolution in metastatic pancreatic cancer: insights from the landmark RASolute-302 trial and emerging allele-specific strategies at ASCO 2026.Semantic proximity Read ↗

Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease.Semantic proximity Read ↗

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.Semantic proximity Read ↗

The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Survival.Semantic proximity Read ↗

Precision medicine for KRAS wild-type pancreatic adenocarcinomas.Semantic proximity Read ↗

Prognostic Implications of Codon-Specific<i>KRAS</i>Mutations in Localized and Advanced Stages of Pancreatic CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.